Thus, approaches targeting CBP/β-catenin combined with PD-1/PD-L1 immune checkpoint blockade represents a novel therapeutic strategy for treating liver metastasis during colon cancer. The gene discussed is CREBBP; the disease is malignant colon neoplasm.